Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma

NCT00084617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage IIIA Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Gastric Cancer

Interventions

DRUG: oxaliplatin
DRUG: irinotecan hydrochloride
DRUG: capecitabine

Sponsor

National Cancer Institute (NCI)